Boosting drug trials: Experts call for collaboration to increase revenue
IV Report
KARACHI: Pakistan's share in global drug efficacy trials is alarmingly low, with only 0.6% of trials conducted locally, experts revealed at a symposium on “Randomised Controlled Clinical Trials”.
Organised by Unesco
Chair at ICCBS, University of Karachi, and Pakistan Academy of Sciences, Sindh
Chapter, on August 29, the event stressed collaboration to boost revenue.
Director of Pharmacy Services, Drug Regulatory Authority of Pakistan (Drap), Dr Zeeshan Nazir shared with the participants of the meeting that only 53 out of 9,000 drugs trials worldwide were being conducted in Pakistan. Pakistan was earning only a fractional of the estimated USD67 billion global revenue, he added, stressing the need for enhanced collaboration between different stakeholders.
On this occasion, Dr Nazir appreciated the
role of the Centre for Bioequivalence Studies and Clinical Research (CBSCR) at
Dr Panjwani Centre for Molecular Medicine and Drug Research, University of
Karachi, in capacity building.
Drap Director further stated that as a regulator Drap was committed to upholding the stringent
quality policy. “At the same time, we will ensure speedy assessments so
that the overall process can be expedited without compromising quality,” he
mentioned and asserted that the role of Drap is crucial as its decisions
directly impact the public health, health care system, and research and
development.
Unesco Chair holder Prof Dr Muhammad Raza Shah highlighted CBSCR's expertise and resources for efficient research.
The professor said that CBSCR offers a unique blend of expertise, resources, and advanced technology all under one roof, enabling the researchers to meet their needs efficiently and effectively. “As a leader in the pharmaceutical services and healthcare industry, the CBSCR continuously innovates to help our partners navigate regulatory challenges and achieve operational excellence,” he asserted.
Dr Zeeshan Nazir of Drap speaking at the symposium.
Comments
Post a Comment